Pruritus: Clinical Trials

496 trials for Pruritus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

325 completed, 42 unknown, 40 recruiting, 32 terminated. 143 Not applicable, 125 Phase 2, 103 Phase 3, 43 Phase 1, 37 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable143Completed 93, Unknown 19, Recruiting 12, Not yet recruiting 9, Active not recruiting 3, Enrolling by invitation 3, Withdrawn 3, Terminated 1
Phase 2125Completed 79, Terminated 17, Not yet recruiting 8, Recruiting 7, Unknown 5, Withdrawn 5, Active not recruiting 4
Phase 3103Completed 72, Terminated 9, Unknown 8, Recruiting 6, Withdrawn 5, Not yet recruiting 2, Active not recruiting 1
Phase 143Completed 32, Terminated 4, Not yet recruiting 2, Recruiting 2, Unknown 2, Withdrawn 1
Phase 437Completed 26, Terminated 4, Not yet recruiting 2, Recruiting 2, Unknown 2, Withdrawn 1
Early Phase 110Completed 6, Not yet recruiting 2, Recruiting 1, Unknown 1

Follow Pruritus: new trials by email Literature Review of Pruritus trials Research Report on Pruritus

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study
Cannabis oil, Placebo - Pruritus
Phase 2Not yet recruitingUniversity Hospital, Brest2182027-01-012026-06-12
Suture Choice for Ostomy Creation
Chromic Gut Suture, Polyglactin 910 Suture - Ostomy - Ileostomy or Colostomy, Stoma Complications
Not applicableNot yet recruitingUniversity of Southern California662027-01-012026-10-28
A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa
Neolizumab - Dystrophic Epidermolysis Bullosa
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Universitaire de Nice152026-12-312026-11-09
Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin
ATTO-1310, Placebo - Chronic Pruritus of Unknown Origin
Phase 2Not yet recruitingAttovia Therapeutics Inc3002026-12-212026-09-22
Topical Minocycline for CARP
Topical Minocycline Foam FXFM244, Control - Confluent and Reticulated Papillomatosis (CARP)
Early Phase 1Not yet recruitingMedical University of South Carolina352026-12-152026-10-22
Evaluating Ceramol Beta Complex® Cream to Relieve Itching After Skin Allergy Tests in Children Aged 6-12 Years (CALM-PRICK)
Application of antipruritic cream, The control group will receive an emollient cream (B), prepared by the hospital pharmacy, without antipruritic or soothing ingredients. - Pruritus
Not applicableNot yet recruitingDolores Lopez Romero1002026-11-012026-11-10
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Roflumilast Cream 0.3%, Vehicle Cream - Atopic Dermatitis, Atopic Dermatitis (AD)
Phase 3RecruitingArcutis Biotherapeutics, Inc.4152026-10-302026-11-06
Observational Analytical Validation Study of the Replior ScratchSense
Scratch and sleep research tracking - Atopic Dermatitis, Pruritus
RecruitingReplior AB352026-10-122026-11-04
J-LINX: Japan LINerixibat eXtension Study
Linerixibat - Pruritus
Phase 3Not yet recruitingGlaxoSmithKline402026-10-092026-10-06
In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan
In vitro antifungal susceptibility testing - Dermatophytosis, Tinea Corporis
RecruitingDr. Amara Safdar1202026-10-022026-10-27
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies
abrocitinib - Dermatitis, Atopic
Not yet recruitingPfizer1202026-10-012026-10-21
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
Lebrikizumab - Prurigo Nodularis (PN)
Phase 2Not yet recruitingUniversity of Maryland, Baltimore152026-09-012026-09-03
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Difelikefalin - Pruritus, Chronic Kidney Diseases
Phase 2RecruitingVifor Fresenius Medical Care Renal Pharma182026-08-042026-10-23
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
Roflumilast Cream 0.15% - ITCH, Atopic Dermatitis
Phase 4RecruitingIntegrative Skin Science and Research402026-07-212026-08-13
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation, Placebo topical formulation - Tinea Pedis
Phase 1RecruitingSinomune Pharmaceutical Co., Ltd642026-07-212026-08-04
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa (EB)
Phase 3RecruitingParadigm Therapeutics802026-07-212026-10-15
High-power Laser Therapy for Notalgia Paresthetica.
High-power laser, Sham Laser - Notalgia Paresthetica
Not applicableRecruitingUşak University402026-07-172026-07-20
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)
Primary Biliary Cholangitis (PBC)
Enrolling by invitationStanford University302026-07-012026-06-11
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel - Skin Pruritus, Itch
Not applicableCompletedNakhia Impex LLC302026-06-202026-09-22
Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis
IL-17 Inhibitor Therapy, Conventional Systemic Therapy - Chronic Plaque-type Psoriasis
RecruitingIstanbul Training and Research Hospital1002026-06-112026-09-28

Showing 20 of 496. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (75)  ·  Tinea Pedis (70)  ·  Eczema (45)  ·  Psoriasis (33)  ·  Pain (24)  ·  Skin Diseases (22)  ·  Urticaria (20)  ·  Kidney Failure, Chronic (19)  ·  Dermatitis (17)  ·  Liver Cirrhosis, Biliary (15)  ·  Renal Insufficiency, Chronic (15)  ·  Chronic Urticaria (14)  ·  Cholestasis (13)  ·  Plaque, Amyloid (10)

Broader conditions

Skin and Connective Tissue Diseases (496)  ·  Pathological Conditions, Signs and Symptoms (494)  ·  Signs and Symptoms (494)  ·  Skin Manifestations (491)  ·  Skin Diseases (474)  ·  Immune System Diseases (119)  ·  Hypersensitivity, Immediate (99)  ·  Skin Diseases, Eczematous (97)  ·  Hypersensitivity (95)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (87)  ·  Dermatitis (85)  ·  Infections (84)  ·  Genetic Diseases, Inborn (83)  ·  Skin Diseases, Genetic (81)  ·  Pathologic Processes (80)

Interventions

Histamine (17)  ·  difelikefalin (13)  ·  Sodium Chloride (9)  ·  secukinumab (9)  ·  Morphine (8)  ·  naftifine (8)  ·  serlopitant (8)  ·  Saline Solution (7)  ·  dupilumab (7)  ·  tofacitinib (7)  ·  Gabapentin (6)  ·  Lidocaine (6)  ·  Tablets (6)  ·  Aprepitant (5)  ·  Blood Specimen Collection (5)

Sponsors

Aalborg University (25)  ·  Novartis Pharmaceuticals (15)  ·  Cara Therapeutics, Inc. (14)  ·  University Hospital, Brest (13)  ·  GlaxoSmithKline (12)  ·  Incyte Corporation (10)  ·  Pfizer (10)  ·  Sun Pharmaceutical Industries, Inc. (8)  ·  Mirum Pharmaceuticals, Inc. (7)  ·  Vyne Therapeutics Inc. (7)  ·  Merz North America, Inc. (6)  ·  University Hospital, Basel, Switzerland (6)  ·  Johns Hopkins University (5)  ·  Pierre Fabre Dermo Cosmetique (4)  ·  Shiraz University of Medical Sciences (4)

Countries

United States (184)  ·  Germany (57)  ·  Canada (52)  ·  Poland (43)  ·  China (40)  ·  France (39)  ·  United Kingdom (32)  ·  Denmark (29)  ·  Spain (29)  ·  Turkey (Türkiye) (24)  ·  Netherlands (20)  ·  Taiwan (20)  ·  Belgium (19)  ·  Hungary (17)  ·  Italy (17)

Top investigators

Gil Yosipovitch, MD (3)  ·  Simon Mueller, PD Dr. med. (3)  ·  Alan Fleischer, MD (2)  ·  Anya Loncaric (2)  ·  Daniel Piacquadio, MD (2)  ·  Dennis West, PhD (2)

Results publications

PMID 33283264, PMID 32816215, PMID 36039153, PMID 33982267, PMID 37968132, PMID 39037824, PMID 11050519, PMID 25971957, PMID 26149717, PMID 28396102, PMID 32632956, PMID 33658996, PMID 33957195, PMID 35305260, PMID 36016762, PMID 36264430, PMID 37341961, PMID 37888917, PMID 37953500, PMID 38698175, PMID 38780109, PMID 39375281, PMID 39546129, PMID 40266487, PMID 41678112, PMID 42825996, PMID 10690153, PMID 11453873, PMID 11525858, PMID 12761013, PMID 12770663, PMID 15471273, PMID 16014882, PMID 16597655, PMID 16918326, PMID 17058231, PMID 17085262, PMID 17175106, PMID 17298105, PMID 17522250, PMID 17535226, PMID 17901734, PMID 18048820, PMID 18181978, PMID 18611915, PMID 18806056, PMID 18809192, PMID 19081121, PMID 19663845, PMID 19692680

NIH funding

2023 (9), 2017 (6), 2018 (4), 2016 (3), 2009 (2), 2015 (2), 2019 (2), 2008 (1), 2014 (1), 2025 (1), R03DK055618 (1), R21AR062357 (1)